After Second Phase III Failure, AstraZeneca Retreats from COPD Filing Plans for Fasenra

AstraZeneca said it’s not planning to seek approvals for Fasenra™ (benralizumab) in chronic obstructive pulmonary disease (COPD) following the drug’s second Phase III trial failure in less than a month.Fasenra missed its primary endpoint in the TERRANOVA Phase III trial ( NCT02155660 ) of a statistically significant reduction of exacerbations, AstraZeneca acknowledged. The company offered no details, saying its full evaluation of data was “ongoing,” and that results